PA
RVNC

Planning Alternatives’s Revance Therapeutics, Inc. RVNC Stock Holding History

Planning Alternatives’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,681
Closed -$326K – 48
2021
Q1 		$326K Hold
11,681
– – 0.05% 38
2020
Q4 		$331K Buy
+11,681
New +$303K 0.06% 37

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Planning Alternatives's RVNC Position: Q2 2021 in Review

Planning Alternatives sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2021, closing a stake of 11,681 shares — an estimated $326K sold.

Planning Alternatives first reported a position in RVNC in Q4 2020 and held it in 2 quarters. The position peaked at $331K in Q4 2020. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2021.

  • Planning Alternatives reported no remaining Revance Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Planning Alternatives sold 11,681 Revance Therapeutics, Inc. shares in Q2 2021, an estimated $326K.
  • Planning Alternatives first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
  • Planning Alternatives's Revance Therapeutics, Inc. position peaked at $331K in Q4 2020.
  • 161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2021.

Based on Planning Alternatives's 13F filing for Q2 2021, filed 15 Jul 2021.